This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic

The EVEREST Trials

Clyde W. Yancy, MD

JAMA. 2007;297:1374-1376. Published online March 25, 2007 (doi:10.1001/jama.297.12.1374).

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of JAMA, 2 articles report findings from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) clinical trials program. Konstam et al¹ report the overall long-term effects of tolvaptan in terms of safety and clinical outcomes for patients with worsening heart failure (HF) requiring hospitalization. Gheorghiade et al² report short-term effects of tolvaptan for acute symptom relief in these same patients, but presented as 2 trials that were based on study center assignment following completion of patient enrollment and randomization in the long-term trial. The aggregate findings demonstrate that tolvaptan relieves some symptoms associated with acute decompensated heart failure (ADHF) and has no demonstrable evidence of harm such as worsening of renal failure, but importantly, does not reduce mortality or HF-related morbidity at 1 year.

In the context of ADHF, these are noteworthy findings. To date, no other . . . [Full Text of this Article]

Author Affiliation: Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Tex.

RELATED ARTICLES

Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial
Marvin A. Konstam, Mihai Gheorghiade, John C. Burnett, Jr, Liliana Grinfeld, Aldo P. Maggioni, Karl Swedberg, James E. Udelson, Faiez Zannad, Thomas Cook, John Ouyang, Christopher Zimmer, Cesare Orlandi, and for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
JAMA. 2007;297(12):1319-1331.
ABSTRACT | FULL TEXT  

Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure: The EVEREST Clinical Status Trials
Mihai Gheorghiade, Marvin A. Konstam, John C. Burnett, Jr, Liliana Grinfeld, Aldo P. Maggioni, Karl Swedberg, James E. Udelson, Faiez Zannad, Thomas Cook, John Ouyang, Christopher Zimmer, Cesare Orlandi, and for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
JAMA. 2007;297(12):1332-1343.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach
Pang et al.
Eur Heart J 2008;29:816-824.
ABSTRACT | FULL TEXT  

Contemporary Trends in the Pharmacological and Extracorporeal Management of Heart Failure: A Nephrologic Perspective
Kazory and Ross
Circulation 2008;117:975-983.
ABSTRACT | FULL TEXT  

JournalScan
Lindsay
Heart 2007;93:1008-1010.
FULL TEXT  

Large Trials of Tolvaptan in Acute Heart Failure
Journal Watch Cardiology 2007;2007:3-3.
FULL TEXT